PE20191542A1 - Estructura cristalina de gremlina 1 y anticuerpo inhibidor - Google Patents

Estructura cristalina de gremlina 1 y anticuerpo inhibidor

Info

Publication number
PE20191542A1
PE20191542A1 PE2019001251A PE2019001251A PE20191542A1 PE 20191542 A1 PE20191542 A1 PE 20191542A1 PE 2019001251 A PE2019001251 A PE 2019001251A PE 2019001251 A PE2019001251 A PE 2019001251A PE 20191542 A1 PE20191542 A1 PE 20191542A1
Authority
PE
Peru
Prior art keywords
gremlin
antibody
gremlina
crystalline structure
antibody inhibitor
Prior art date
Application number
PE2019001251A
Other languages
English (en)
Inventor
Neesha Dedi
Breda Twomey
Michael John Wright
Gareth Davies
David James Mcmillan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of PE20191542A1 publication Critical patent/PE20191542A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Referido a un anticuerpo, el cual se une a un epitopo sobre gremlina 1, que comprende al menos un residuo seleccionado de Ile131, Lys147, Lys148, Phe149, Thr150, Thrl51, Argl69, Lysl74 y Gin 175, donde la numeracion de los residuos es de conformidad con la SEQ ID NO: 1. Dichos anticuerpos se unen a un sitio inhibidor alosterico en la gremlina 1 y son utiles en el tratamiento y prevencion de la fibrosis renal como nefropatia diabetica, fibrosis pulmonar idiopatica, hipertension, entre otras. Ademas, se refiere a un polinucleotido, un vector, una celula huesped que codifica dicho anticuerpo, una forma cristalina de gremlina 1 y una composicion farmaceutica que comprende dichos anticuerpos
PE2019001251A 2016-12-19 2017-12-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor PE20191542A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1621635.0A GB201621635D0 (en) 2016-12-19 2016-12-19 Crystal structure
PCT/EP2017/083650 WO2018115017A2 (en) 2016-12-19 2017-12-19 Gremlin-1 crystal structure and inhibitory antibody

Publications (1)

Publication Number Publication Date
PE20191542A1 true PE20191542A1 (es) 2019-10-23

Family

ID=58284547

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001251A PE20191542A1 (es) 2016-12-19 2017-12-19 Estructura cristalina de gremlina 1 y anticuerpo inhibidor

Country Status (27)

Country Link
US (3) US10947304B2 (es)
EP (1) EP3555129A2 (es)
JP (1) JP7097364B2 (es)
KR (1) KR102557216B1 (es)
CN (1) CN110099924B (es)
AR (1) AR110394A1 (es)
AU (1) AU2017384471A1 (es)
BR (1) BR112019010903A2 (es)
CA (1) CA3045742A1 (es)
CL (1) CL2019001715A1 (es)
CO (1) CO2019006073A2 (es)
EA (1) EA201991511A1 (es)
EC (1) ECSP19051912A (es)
GB (1) GB201621635D0 (es)
IL (1) IL267287A (es)
MA (1) MA47669A (es)
MX (1) MX2019006630A (es)
MY (1) MY202395A (es)
PE (1) PE20191542A1 (es)
PH (1) PH12019501319A1 (es)
RU (1) RU2769285C2 (es)
TN (1) TN2019000188A1 (es)
TW (1) TWI787223B (es)
UA (1) UA126025C2 (es)
UY (1) UY37528A (es)
WO (1) WO2018115017A2 (es)
ZA (1) ZA201903810B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) * 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
WO2019243801A1 (en) * 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
WO2022188856A1 (en) * 2021-03-11 2022-09-15 Shanghai Jiao Tong University Method of treating diseases using gremlin1 antagonists
GB202205200D0 (en) 2022-04-08 2022-05-25 Ucb Biopharma Sprl Combination with chemotherapy
GB202205203D0 (en) 2022-04-08 2022-05-25 UCB Biopharma SRL Combination with inhibitor
WO2023203177A1 (en) * 2022-04-20 2023-10-26 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
JP4603894B2 (ja) 2002-12-03 2010-12-22 ユセベ ファルマ ソシエテ アノニム 抗体産生細胞を同定するためのアッセイ
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
ES2622460T3 (es) 2007-09-26 2017-07-06 Ucb Biopharma Sprl Fusiones de anticuerpos con doble especificidad
WO2013137686A1 (ko) 2012-03-15 2013-09-19 서울대학교 산학협력단 그렘린-1에 대한 항체
CN105189548A (zh) * 2013-03-14 2015-12-23 瑞泽恩制药公司 Grem1的人抗体
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
WO2019243801A1 (en) 2018-06-18 2019-12-26 UCB Biopharma SRL Gremlin-1 antagonist for the prevention and treatment of cancer

Also Published As

Publication number Publication date
RU2769285C2 (ru) 2022-03-30
IL267287A (en) 2019-08-29
GB201621635D0 (en) 2017-02-01
TWI787223B (zh) 2022-12-21
UA126025C2 (uk) 2022-08-03
CA3045742A1 (en) 2018-06-28
CO2019006073A2 (es) 2019-06-19
WO2018115017A3 (en) 2019-02-07
MX2019006630A (es) 2019-08-21
PH12019501319A1 (en) 2020-03-02
CN110099924B (zh) 2023-11-10
KR102557216B1 (ko) 2023-07-18
CL2019001715A1 (es) 2019-11-29
AU2017384471A1 (en) 2019-06-13
KR20190093658A (ko) 2019-08-09
ECSP19051912A (es) 2019-07-31
RU2019122648A3 (es) 2021-07-02
JP2020511946A (ja) 2020-04-23
TN2019000188A1 (en) 2020-10-05
JP7097364B2 (ja) 2022-07-07
UY37528A (es) 2018-07-31
US11807680B2 (en) 2023-11-07
US20240076365A1 (en) 2024-03-07
MA47669A (fr) 2020-01-08
RU2019122648A (ru) 2021-01-19
US20190330323A1 (en) 2019-10-31
MY202395A (en) 2024-04-25
CN110099924A (zh) 2019-08-06
WO2018115017A2 (en) 2018-06-28
AR110394A1 (es) 2019-03-27
US10947304B2 (en) 2021-03-16
TW201837052A (zh) 2018-10-16
US20210163586A1 (en) 2021-06-03
EP3555129A2 (en) 2019-10-23
EA201991511A1 (ru) 2019-11-29
BR112019010903A2 (pt) 2019-10-01
ZA201903810B (en) 2020-12-23

Similar Documents

Publication Publication Date Title
PE20191542A1 (es) Estructura cristalina de gremlina 1 y anticuerpo inhibidor
AR118047A2 (es) Anticuerpo aislado o fragmento del mismo, composición farmacéutica y molécula biespecífica
ECSP15049909A (es) Composiciones y métodos para alterar la señalización del segundo mensajero
CL2017002435A1 (es) Compuestos de aldehído para el tratamiento de fibrosis pulmonar, hipoxia, y enfermedad del tejido conectivo y autoinmune.
UY37141A (es) Anticuerpos dirigidos a tigit
CL2019002609A1 (es) Compuestos heterocíclicos útiles como inhibidores dobles atx/ca.
EA201990565A1 (ru) Кристаллический 19-нор c3,3-дизамещенный c21-n-пиразолил стероид
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
EA201792536A1 (ru) Триазоловые агонисты рецептора apj
SV2018005662A (es) Moduladores del receptor x farnesoide
CL2012002095A1 (es) Polipéptido de unión biparatópico que comprende un primer dominio variable individual de inmunoglobulina (ig) que se une específicamente a un primer epítopo del péptido ß-amiloide (ßa) y un segundo dominio variable de ig que se une específicamente a un segundo epítopo del ßa, donde dichos epítopos del ßa no son idénticos; ácido nucleico que lo codifica; vector; célula hospedera; composición farmacéutica; método de preparación; y su uso en el tratamiento y/o prevención de depósitos del ßa
AR087113A1 (es) Metodo de cementado y composicion
AR101846A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
CL2018000711A1 (es) Anticuerpos que se unen específicamente a tl1a
BR112017018276A2 (pt) ?composição que compreende peptidase e biotensoativo e seu uso?
AR090339A1 (es) Metodos de pronostico, diagnostico y tratamiento de la fibrosis pulmonar idiopatica
CO2018012258A2 (es) Compuestos de mic-1 y usos de estos
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
CL2017000271A1 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CR20180143A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca
CL2017003189A1 (es) Anticuerpo que se une a tnf-alfa trimérico
CL2014000996A1 (es) Compuestos derivados de 2-tiopirimidinonas, como inhibidores de mieloperoxidasa; composicion y combinacion farmaceutica que los comprende, util para tratar afecciones y eventos cardiovasculares tales como insuficiencia cardiaca, hipertension pulmonar, infarto de miocardio primario o secundario e isquemia.
EA201790415A1 (ru) ЛИОФИЛИЗИРОВАННЫЕ СОСТАВЫ ДЛЯ АНТИДОТА ФАКТОРА Xa
ECSP19033211A (es) ANTICUERPOS ANTI–C1s Y MÉTODOS DE USO DE LOS MISMOS